Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 17 of 17 entries
View as:

A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03324243 Org: User:
Start: 01/31/18 End: 12/31/20 Due: 12/31/21

A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

Phase: N/A Priority: Normal
NCT ID: NCT02283177 Org: User:
Start: 01/31/15 End: 12/31/19 Due: 12/31/20

A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.

Phase: N/A Priority: Normal
NCT ID: NCT00386555 Org: User:
Start: 05/31/07 End: - Due: -

Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST

Phase: N/A Priority: Normal
NCT ID: NCT02847429 Org: User:
Start: 08/31/16 End: 08/31/21 Due: 08/31/22

CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00949624 Org: User:
Start: 12/31/05 End: 06/30/08 Due: 06/30/09

Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene

Phase: N/A Priority: Normal
NCT ID: NCT01243346 Org: User:
Start: 04/30/11 End: 07/31/14 Due: 07/31/15

Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients

Phase: N/A Priority: Normal
NCT ID: NCT02400255 Org: User:
Start: 09/30/15 End: 05/31/22 Due: 05/31/23

Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification

Phase: N/A Priority: Normal
NCT ID: NCT02626364 Org: User:
Start: 04/30/16 End: 07/31/20 Due: 07/31/21

Individual Patient Compassionate Use of Crenolanib

Phase: N/A Priority: Normal
NCT ID: NCT03620318 Org: User:
Start: - End: - Due: -

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

Phase: N/A Priority: Normal
NCT ID: NCT02626338 Org: User:
Start: 02/29/16 End: 02/28/18 Due: 02/28/19

Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03193918 Org: User:
Start: 04/14/17 End: 07/15/20 Due: 07/15/21

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

Phase: N/A Priority: Normal
NCT ID: NCT02400281 Org: User:
Start: 09/30/15 End: 07/15/20 Due: 07/15/21

Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations

Phase: N/A Priority: Normal
NCT ID: NCT01522469 Org: User:
Start: 07/31/12 End: 11/30/14 Due: 11/30/15

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Phase: N/A Priority: Normal
NCT ID: NCT03250338 Org: User:
Start: 06/05/18 End: 10/31/24 Due: 10/31/25

A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations

Phase: N/A Priority: Normal
NCT ID: NCT01657682 Org: User:
Start: 10/31/12 End: 04/30/19 Due: 04/30/20

Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas

Phase: N/A Priority: Normal
NCT ID: NCT01229644 Org: User:
Start: 04/30/11 End: 12/31/12 Due: 12/31/13

Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Phase: N/A Priority: Normal
NCT ID: NCT03258931 Org: User:
Start: 08/15/18 End: 11/30/24 Due: 11/30/25